Group items tagged

The Children's Heart Foundation's 2020 Call for Research Proposals is now open! The Children's Heart Foundation funds life-saving, life-changing congenital heart defect (CHD) research in clinical cardiology, translational research, population science, and advancement, prevention, detection of surgical and interventional techniques including, but not limited to the following areas:  Genetics Biochemistry Pharmacology Devices and procedural research (cardiac catheterization and surgery) Neurodevelopmental and functional outcomes Quality and policy regarding delivery of care, coverage, and access Maternal environment and modifiable disease impact on fetuses with CHD Fetal diagnosis and intervention Long-term care of adults with CHDs Technological development and advancements

The BrightFocus Foundation funds scientific research worldwide to defeat Alzheimer's disease, macular degeneration, and glaucoma and provides expert information on these heartbreaking diseases. To advance this mission, the foundation welcomes applications for its National Glaucoma Research Grant. Through the program, grants of up to $100,000 a year for up to two years will be awarded in support of pioneering research leading to greater understanding, prevention, and treatment of glaucoma.

This Funding Opportunity Announcement (FOA) solicits research projects focused on the process of effective communication of research findings about breast cancer and the environment. A central objective of this new initiative is to ensure effective translation of findings that result in risk messaging that is understood by targeted audiences.  The ultimate goal is to provide the scientific evidence for developing communication-based prevention efforts to reduce the risk for breast cancer from environmental factors.  

The purpose of this funding opportunity announcement (FOA) is to encourage grant applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy.

The purpose of this funding opportunity announcement (FOA) is to encourage grant applications that will identify molecular targets for pregnancy associated/induced disorders and will lead to the development of new safer and more effective medications for use in pregnancy.

This Funding Opportunity Announcement invites applications for a U24 Telomere Research Network/Collaboratory. This U24 will coordinate activities of a telomere length (TL) methods comparison study involving multiple labs supported under U01 awards made in response to FOA (RFA-AG-19-023) to address the need for cross-validation between protocols and samples for establishing best practices for population-based TL research. The U24 will serve as the central resource for the organization of meetings and other activities of this coordinated program, including support for the methods study, dissemination of its results and resultant recommendations. It will also develop and foster an extended Telomere Research Network (TRN) connecting the broader field through a flexible range of activities that will advance an interdisciplinary research agenda on telomeres and activities directly associated with TL maintenance as sentinels of environmental exposures, psychosocial stress, and disease susceptibility.

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social principles and processes that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants

The overall purpose of this funding opportunity announcement (FOA) is to assess the role of the microbiome in health and disease during aging. This initiative will support research projects designed to evaluate changes in the microbiota during lifetime and its influence in health and disease status in the elderly, including those from racial/ethnic minority and underserved populations and understand the underlying mechanisms of microbiota interactions in aged subjects as related to health and disease. This FOA will support basic mechanistic, preclinical studies in animal models and human clinical trial proposals in accordance with the state of the science.

The purpose of this NOFO is to provide support for:Communication and education activities to promote and maintain accurate information about vaccines among stakeholders and the general publicEducation of USDA/WIC staff about the latest vaccine recommendations and vaccine access points to facilitate vaccination referrals to WIC participants

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with Mycobacterium tuberculosis (Mtb) and/or tuberculosis disease (TB).

The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on establishing proof-of-concept for and/or preclinical development of lead candidate vaccines targeting infection with Mycobacterium tuberculosis (Mtb) and/or tuberculosis disease (TB).   

Currently, the drugs are designed in such a way that the active pharmaceutical ingredient (API) is immediately released in the stomach and absorbed in the bloodstream, rapidly relieving the patient from his/her pain (left-hand side). In case multiple doses are taken all at once, a (potentially toxic) supratherapeutic amount of API immediately gets into the user's bloodstream (center). This amount is illicitly used to induce euphoria and could be potentially toxic. Grünenthal's intention is to design a drug formulation that guarantees the API's release profile in case of proper therapeutical usage. However, in case multiple drug units are taken, the release of API, that is available for absorption (right-hand side), will be limited or, at least, decreased to avoid overdosing.

To that end, the two organizations have issued a Request for Applications for projects that test feasibility and generate preliminary data. MRA and ACS have each committed $1 million for the awards. The combined $2 million will be used to fund Multidisciplinary Team Awards and Pilot Awards. 1) Multidisciplinary Team Awards: At least one grant of up to $1 million will be awarded in this category are designed to foster interdisciplinary collaborative research to promote transformational advances with the potential for rapid clinical benefit. Letters of Intent must be received no later than August. Upon review, selected applicants will be invited to submit full applications by October 31, 2017. 2) Pilot Awards: Up to five grants of up to $200,000 each will be awarded over two years to help seed the ground in this relatively young area of checkpoint irAE research. Applications must be received no later than October 16, 2017.

The purpose of this initiative is to support research to determine the underlying mechanisms of how HIV related co-morbidities may influence the complexity of HIV/AIDS disease progression, quality of life and overall health outcomes among HIV positive individuals from health disparity populations.

There is a devastating opioid use and overdose crisis in the United States. It has been reported that approximately 25.5 million adults suffer pain and opioids that are often prescribed for their treatment can lead to opioid misuse and dependence. It has also been reported that more than 2 million Americans have OUDs and many started their addiction with prescribed opioids. One of the most devastating consequences of opioid misuse is opioid overdose, which can produce respiratory depression and death. Drug overdose is the leading cause of accidental death in the US, with an estimation of 60,000 deaths in 2016; 20,101 overdose deaths related to prescription pain relievers, and 12,990 overdose deaths related to heroin.

The purpose of this Funding Opportunity Announcement (FOA) is to support hypothesis-generating research in transgender people with the objective of characterizing the biological and immunological impact of the interventions (hormones, drugs and surgical) used for gender reassignment and their impact on susceptibility to HIV and other sexually transmitted infections (STI).